|
시장보고서
상품코드
2078702
기관지 경련 시장 : 시장 규모, 점유율 및 성장 분석 - 진단 검사법별, 치료제 유형별, 투여 경로별, 대상 환자층별, 지역별 업계 예측(2026-2033년)Bronchial Spasm Market Size, Share, and Growth Analysis, By Diagnostic Testing Modality, By Treatment Medication Class, By Route of Administration, By Target Patient Demographic, By Region - Industry Forecast 2026-2033 |
||||||
세계의 기관지 경련 시장 규모는 2024년에 38억 8,000만 달러로 평가되었고, 2025년 40억 4,000만 달러에서 2033년까지 56억 3,000만 달러로 확대될 전망이며, 예측 기간(2026-2033년) CAGR 4.23%로 성장할 전망입니다.
세계의 기관지 경련 시장에는 천식, 만성폐쇄성폐질환(COPD) 및 알레르기 반응에 따른 급성 기도 협착을 완화하기 위한 의약품, 생물학적 제제, 의료기기가 포함됩니다. 호흡기 질환의 유병률이 높고, 이는 의료 시스템에 막대한 재정적 부담을 초래하고 있다는 점을 고려할 때, 이 시장은 매우 중요합니다. 제네릭 기관지 확장제에서 항-IL-5 항체 등의 생물학적 제제를 포함한 첨단 치료법으로의 전환은 조절 불가능한 기관지 경련에 대한 임상적 이해가 깊어지고 있음을 보여주며, 제약사의 연구 투자 확대를 촉진하고 있습니다. 새로운 성장 요인으로는 환자의 표현형을 기반으로 한 표적 치료로의 전환을 들 수 있습니다. 이는 치료 효과를 높일 뿐만 아니라, 의료비 절감과 환자의 삶의 질 향상으로도 이어집니다. 그 결과, 보험사의 수용도가 높아져 보험 적용 범위가 확대되는 동시에, 진단 기업과의 제휴를 통해 동반 진단이 추진되면서, 호흡기 질환의 부담이 증가하고 있는 신흥 시장에서 성장의 길이 열리고 있습니다.
세계 기관지 경련 시장의 성장 요인
세계 기관지 경련 시장의 주요 성장 요인 중 하나는 천식이나 만성 폐쇄성 폐질환(COPD)과 같은 호흡기 질환의 유병률 증가입니다. 환경 오염 물질, 흡연, 알레르기 유발 물질 증가로 인해 기관지 경련의 위험에 노출되는 인구가 늘어나고 있으며, 효과적인 치료법의 필요성이 커지고 있습니다. 또한, 제약 연구 개발의 진전과 기관지 수축의 특정 경로를 표적으로 하는 혁신적인 치료법의 개발이 시장 성장을 더욱 촉진하고 있습니다. 호흡기 건강과 적시적인 의료 개입의 중요성에 대한 인식이 높아짐에 따라, 효과적인 기관지 경련 관리 솔루션에 대한 수요는 계속해서 증가하고 있습니다.
세계 기관지 경련 시장의 제약 요인
세계 기관지 경련 시장의 주요 제약 요인 중 하나는 치료법의 승인 및 판매와 관련된 엄격한 규제 환경입니다. 규제 당국의 승인을 얻기 위한 절차는 복잡하고 오랜 시간이 걸리기 때문에 신약이나 새로운 치료법의 도입이 지연되고, 혁신이 저해되며, 환자의 선택권이 제한될 가능성이 있습니다. 또한, 안전성과 유효성을 확보하기 위해 요구되는 엄격한 시험 프로토콜은 개발 비용 증가로 이어져, 중소규모 기업이나 스타트업 시장 진입을 저해할 가능성이 있습니다. 또한, 의료 종사자들의 기관지 경련에 대한 인식과 이해 부족은 환자의 진단 누락이나 치료 부족을 초래할 우려가 있으며, 이는 시장 성장을 더욱 제한하는 요인이 될 수 있습니다.
세계의 기관지 경련 시장 동향
세계의 기관지 경련 시장에서는 유전체 프로파일링 및 바이오마커 발견의 진전을 배경으로, 맞춤형 치료로의 뚜렷한 추세가 나타나고 있습니다. 이러한 변화로 인해 임상의들은 환자의 고유한 표현형을 바탕으로 치료 계획을 맞춤형으로 수립할 수 있게 되었으며, 기존의 획일적인 기관지 확장제 치료 방식에서 점차 벗어나고 있습니다. 그 결과, 각 제약사는 특정 염증 경로를 표적으로 하는 틈새 시장용 제제나 병용 요법의 개발에 주력할 수밖에 없게 되었으며, 이를 통해 유효성과 안전성 프로파일이 개선되고 있습니다. 헬스케어 제도가 정밀 의학을 점점 더 도입함에 따라, 보험 환급 모델도 표적 치료를 우선시하는 방향으로 변화하고 있습니다. 이러한 변화하는 상황은 진단제 제조업체와 치료제 제조업체 간의 협력을 촉진하고, 전 세계적인 차원에서 맞춤형 의료 솔루션의 통합을 뒷받침하고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
주요 요약
시장 역학 및 전망
주요 시장 인사이트
세계의 기관지 경련 시장 규모 : 진단 검사법별
세계의 기관지 경련 시장 규모 : 치료제 유형별
세계의 기관지 경련 시장 규모 : 투여 경로별
세계의 기관지 경련 시장 규모 : 대상 환자층별
세계의 기관지 경련 시장 규모 : 유통 채널별
세계의 기관지 경련 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론 및 제안
AJY 26.07.13Global Bronchial Spasm Market size was valued at USD 3.88 Billion in 2024 and is poised to grow from USD 4.04 Billion in 2025 to USD 5.63 Billion by 2033, growing at a CAGR of 4.23% during the forecast period (2026-2033).
The global bronchial spasm market encompasses pharmaceuticals, biologics, and medical devices aimed at alleviating acute airway constriction associated with asthma, COPD, and allergic responses. Given the high prevalence of respiratory issues, which significantly burden healthcare systems financially, this market is crucial. The evolution from generic bronchodilators to advanced therapies, including biologics like anti-IL-5 antibodies, highlights enhanced clinical insights into uncontrolled bronchial spasms, prompting increased manufacturer investment in research. An emerging growth driver is the transition to targeted therapies based on patient phenotypes, which not only enhances treatment efficacy but also reduces healthcare costs and improves patient quality of life. Consequently, payer acceptance increases, leading to expanded reimbursement, while partnerships with diagnostic firms advance companion diagnostics, paving the way for growth in emerging markets facing rising respiratory disease burdens.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Bronchial Spasm market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Bronchial Spasm Market Segments Analysis
Global bronchial spasm market is segmented by diagnostic testing modality, treatment medication class, route of administration, target patient demographic, distribution procurement channel and region. Based on diagnostic testing modality, the market is segmented into Spirometry Pulmonary Tests, Clinical Imaging Tests and Lab Biomarker Assays. Based on treatment medication class, the market is segmented into Bronchodilators, Corticosteroids, Leukotriene Antagonists and Combination Drug Formulations. Based on route of administration, the market is segmented into Inhalational Therapy, Oral Dosages and Parenteral Injections. Based on target patient demographic, the market is segmented into Pediatric Cases, Adult Cases and Geriatric Cases. Based on distribution procurement channel, the market is segmented into Institutional Hospital Pharmacies, Retail Pharmacies and Outlets and Online E-Commerce Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Bronchial Spasm Market
One of the key market drivers for the Global Bronchial Spasm Market is the rising prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The increasing incidence of environmental pollutants, tobacco use, and allergens contributes to a growing population at risk for bronchial spasms, necessitating effective treatment options. Moreover, advancements in pharmaceutical research and the development of innovative therapies that target specific pathways of bronchial constriction further fuel market growth. As awareness regarding respiratory health and the importance of timely medical interventions rises, demand for effective bronchial spasm management solutions continues to expand.
Restraints in the Global Bronchial Spasm Market
One significant restraint in the global bronchial spasm market is the stringent regulatory environment surrounding the approval and marketing of treatments. The complex and lengthy process for obtaining regulatory approvals can delay the introduction of new medications and therapies, hindering innovation and limiting options for patients. Additionally, the rigorous testing protocols required to ensure safety and efficacy contribute to increased development costs, which may deter smaller companies and startups from entering the market. Moreover, a lack of awareness and understanding of bronchial spasm conditions among healthcare providers can further restrict market growth, as it may lead to underdiagnosis and undertreatment of affected patients.
Market Trends of the Global Bronchial Spasm Market
The global bronchial spasm market is witnessing a significant trend towards personalized therapy, driven by advancements in genomic profiling and biomarker discovery. This shift enables clinicians to customize treatment plans for patients based on their unique phenotypes, steering away from traditional, generalized bronchodilator approaches. Consequently, pharmaceutical companies are compelled to innovate with niche formulations and combination therapies that specifically target distinct inflammatory pathways, thereby improving efficacy and safety profiles. As healthcare systems increasingly embrace precision medicine, reimbursement models are adapting to favor targeted interventions. This evolving landscape is fostering greater collaboration between diagnostics and therapeutics companies, facilitating the integration of personalized healthcare solutions on a global scale.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Bronchial Spasm Market Size by Diagnostic Testing Modality & CAGR (2026-2033)
- Market Overview
- Spirometry Pulmonary Tests
- Forced Expiratory Volume Measurements
- Forced Vital Capacity Evaluation
- Clinical Imaging Tests
- High-Resolution Computed Tomography
- Chest X-Ray Screening
- Lab Biomarker Assays
Global Bronchial Spasm Market Size by Treatment Medication Class & CAGR (2026-2033)
- Market Overview
- Bronchodilators
- Short-Acting Beta-Agonists
- Long-Acting Beta-Agonists
- Long-Acting Muscarinic Antagonists
- Corticosteroids
- Leukotriene Antagonists
- Combination Drug Formulations
Global Bronchial Spasm Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Inhalational Therapy
- Oral Dosages
- Parenteral Injections
Global Bronchial Spasm Market Size by Target Patient Demographic & CAGR (2026-2033)
- Market Overview
- Pediatric Cases
- Adult Cases
- Geriatric Cases
Global Bronchial Spasm Market Size by Distribution Procurement Channel & CAGR (2026-2033)
- Market Overview
- Institutional Hospital Pharmacies
- Retail Pharmacies and Outlets
- Online E-Commerce Pharmacies
Global Bronchial Spasm Market Size & CAGR (2026-2033)
- North America (Diagnostic Testing Modality, Treatment Medication Class, Route of Administration, Target Patient Demographic, Distribution Procurement Channel)
- US
- Canada
- Europe (Diagnostic Testing Modality, Treatment Medication Class, Route of Administration, Target Patient Demographic, Distribution Procurement Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Diagnostic Testing Modality, Treatment Medication Class, Route of Administration, Target Patient Demographic, Distribution Procurement Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Diagnostic Testing Modality, Treatment Medication Class, Route of Administration, Target Patient Demographic, Distribution Procurement Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Diagnostic Testing Modality, Treatment Medication Class, Route of Administration, Target Patient Demographic, Distribution Procurement Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co. Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hikma Pharmaceuticals PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Glenmark Pharmaceuticals Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alkem Laboratories Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Torrent Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aurobindo Pharma Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Lifesciences Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Wockhardt Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
